Abstract
Rationale To determine a long-term response of VKC to 0.1% topical FK-506 treatment. Methods Ten chronic cases (9 boys) of VKC were enrolled with mean ages of 9.12 ± 2.45 yrs. The mean duration of VKC was 3.97 ± 1.96 yrs. They were successful treated with 0.1% FK-506 ophthalmic ointment in our earlier report (4weeks). Frequencies of FK 506 were then decreased according to symptoms. They were followed monthly to every 2 months. Eye symptoms and side effect were monitored. Blood levels of FK506 were determined at 4 weeks and 6 months after initial treatment. CBC, renal and liver functions were obtained at baseline and every 6 months. Results Six patients were able to discontinue the use of FK506 (with 1 day to 1 week intermittent use) whereas 4 patients require once daily treatment. There was a significant reduction tarsal papilla (from 1.09 ± 0.64 mm to 0.38 ± 0.39 mm, p=0.01). Blood FK506 levels were undetectable with normal laboratory results in all patients. Both patients and physician rated high preference for the treatment. Conclusion The use of FK506 brought about remission of VKC in 6 patients during this 1 year observation period.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
